POS0198 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL - Concepedia

Concepedia

Publication | Closed Access

POS0198 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

14

Citations

0

References

2021

Year

Philip J. Mease, Atul Deodhar, D. van der Heijde, Frank Behrens, Alan Kivitz, J. Kim, Shalabh Singhal, Miroslawa Nowak, Susana Banerjee

Annals of the Rheumatic Diseases

No additional data available for this publication yet. Check back later!